Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound doubled in the fourth quarter year over year, despite ...

U.S. markets closed mixed with S&P 500 and Nasdaq gaining, while Dow slipped. Economic data exceeded expectations, while commodities and futures showed mixed results. Markets await key reports and ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...

Bain Capital said its decision to buy Mitsubishi Tanabe is due to the “strong growth potential” of Japan’s healthcare ...

After suffering a heartbreaking loss in the NWSL semifinals, Gotham experienced some roster shake-up this winter and needs ...

Group announced that its board of directors has authorized a share repurchase program to buy back up to $30M of its ...

Friday announced that its board has authorized to buy back up to $30 million of its outstanding Class A ordinary shares. The Company may repurchase shares from time to time on the open market or in ...

PEDMARQSI is the First and Only Approved Therapy in the EU and U.K. for the Prevention of Ototoxicity, or Hearing Loss, Induced by Cisplatin Chemotherapy in Patients 1 month to <18 Years of Age with ...